Related references
Note: Only part of the references are listed.FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
Philip N. Newsome et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease
Shalimar et al.
INDIAN JOURNAL OF GASTROENTEROLOGY (2020)
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib
Saumya Jayakumar et al.
JOURNAL OF HEPATOLOGY (2019)
Non-alcoholic fatty liver disease - A global public health perspective
Zobair M. Younossi
JOURNAL OF HEPATOLOGY (2019)
Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials
Cyrielle Caussy et al.
HEPATOLOGY (2018)
Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients
Harshit Garg et al.
SURGERY FOR OBESITY AND RELATED DISEASES (2018)
Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis
Eric Nguyen-Khac et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis
JOURNAL OF HEPATOLOGY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Utility and Appropriateness of the Fatty Liver Inhibition of Progression (FLIP) Algorithm and Steatosis, Activity, and Fibrosis (SAF) Score in the Evaluation of Biopsies of Nonalcoholic Fatty Liver Disease
Pierre Bedossa
HEPATOLOGY (2014)
Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008
Zobair M. Younossi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Complication Rate of Percutaneous Liver Biopsies Among Persons With Advanced Chronic Liver Disease in the HALT-C Trial
Leonard B. Seeff et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
Paul Angulo et al.
HEPATOLOGY (2007)
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
Richard K. Sterling et al.
HEPATOLOGY (2006)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C
CT Wai et al.
HEPATOLOGY (2003)
Share Paper
